|
gptkbp:instanceOf
|
gptkb:antibiotic
cephalosporin
|
|
gptkbp:activeIn
|
gptkb:methicillin-resistant_Staphylococcus_aureus
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J01DI02
|
|
gptkbp:brand
|
gptkb:Teflaro
|
|
gptkbp:CASNumber
|
636160-18-2
|
|
gptkbp:chemicalFormula
|
C14H15N5O5S2
|
|
gptkbp:contraindication
|
hypersensitivity to cephalosporins
|
|
gptkbp:developedBy
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Forest_Laboratories
|
|
gptkbp:eliminationHalfLife
|
2.6 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ceftaroline
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial cell wall synthesis
|
|
gptkbp:metabolism
|
hydrolysis to active metabolite
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
11561899
CHEMBL2107726
DB06590
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
headache
rash
|
|
gptkbp:spectrumOfActivity
|
Gram-negative bacteria
Gram-positive bacteria
|
|
gptkbp:synonym
|
gptkb:ceftaroline_fosamil
gptkb:ceftaroline_fosamil_acetate
|
|
gptkbp:UNII
|
Q1J8A4B08K
|
|
gptkbp:usedFor
|
bacterial infections
community-acquired pneumonia
acute bacterial skin and skin structure infections
|
|
gptkbp:bfsParent
|
gptkb:cephalosporins
|
|
gptkbp:bfsLayer
|
6
|